Engineering albumin-hitchhiking drug formulations to develop more effective therapeutic cancer vaccines
Therapeutic cancer vaccines have great potential in the treatment of a variety of cancer types, but there is significant room for improvement before vaccines become commonplace in oncology. Recent evidence indicates that subcutaneous injection of amphiphilic vaccine formulations bind albumin, and this interaction promotes more efficient delivery of the vaccine to local lymph nodes, resulting in more effective vaccine responses. However, the molecular details remain undetermined. The purpose of this project is to elucidate the mechanisms behind the phenomenon and translate these findings into more effective cancer vaccine formulations.